Adial Pharmaceuticals delays shareholder meeting vote on proposals 3-6 to Oct. 15 pending Nasdaq approval

• Adial Pharmaceuticals delayed votes on four shareholder proposals tied to a Nasdaq initial listing application still awaiting approval.
• The annual meeting, reconvened Oct. 1, was adjourned again with polls remaining open on the deferred items.
• Next session is set for Oct. 15, 2026 at 8:30 a.m. ET at the company’s Charlottesville, Virginia offices.
• Record date stays Aug. 17, 2026; previously submitted proxies remain valid unless shareholders change their votes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106395), on October 02, 2026, and is solely responsible for the information contained therein.